Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Tempestuous Course of Enterococcus Infective Endocarditis — From Daptomycin Lung Toxicity to Successful Treatment With Surgery and Fosfomycin Combination Therapy
We report a patient with E. faecalis IE who had allergy to β-lactam and during treatment had developed daptomycin lung toxicity. He was subsequently treated with intravenous fosfomycin and surgery with aortic valve replacement.
Source: Infectious Diseases in Clinical Practice - March 1, 2020 Category: Infectious Diseases Tags: Case Reports Source Type: research
NIH clinical trial of investigational vaccine for COVID-19 begins
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against COVID-19 has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), is funding the trial. KPWHRI is part of NIAID's Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today.
Source: EurekAlert! - Infectious and Emerging Diseases - March 16, 2020 Category: Infectious Diseases Source Type: news
NIH clinical trial tests remdesivir plus anti-inflammatory drug baricitinib for COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for COVID-19 has begun. The trial is now enrolling hospitalized adults with COVID-19 in the United States. The trial is expected to open at approximately 100 US and international sites. Investigators currently anticipate enrolling more than 1,000 participants. The National Institute of Allergy and Infectious Diseases is sponsoring the trial.
Source: EurekAlert! - Infectious and Emerging Diseases - May 8, 2020 Category: Infectious Diseases Source Type: news
NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus disease 2019 (COVID-19). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG). Teva Pharmaceuticals is donating medications for the study.
Source: EurekAlert! - Infectious and Emerging Diseases - May 14, 2020 Category: Infectious Diseases Source Type: news
NIH trial to test antibodies and other therapeutics for mild, moderate COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, are working with clinical sites to identify potential patient volunteers currently infected with SARS-CoV-2, the virus which causes COVID-19, who have mild to moderate disease not requiring hospitalization.
Source: EurekAlert! - Infectious and Emerging Diseases - August 4, 2020 Category: Infectious Diseases Source Type: news
Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19 disease.
Source: EurekAlert! - Infectious and Emerging Diseases - September 30, 2020 Category: Infectious Diseases Source Type: news
With or without allergies, outcomes similar for hospitalized patients with COVID-19
(American College of Allergy, Asthma, and Immunology) A new study being presented at this year's virtual American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting examines hospital data to determine if those with allergic conditions had more severe COVID-related disease than those without.
Source: EurekAlert! - Infectious and Emerging Diseases - November 13, 2020 Category: Infectious Diseases Source Type: news
NIH announces restructured HIV clinical trials networks
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years to conduct the innovative, efficient clinical research needed to accelerate progress against the HIV pandemic. NIAID also awarded grants to 35 U.S. and international institutions selected as HIV clinical trials units (CTUs).
Source: EurekAlert! - Infectious and Emerging Diseases - November 30, 2020 Category: Infectious Diseases Source Type: news
NIH officials highlight COVID-19 vaccine facts, unknowns for healthcare providers
(NIH/National Institute of Allergy and Infectious Diseases) Healthcare providers must be able to explain the latest data supporting the safety and efficacy of vaccines for coronavirus disease 2019 (COVID-19) so they can strongly encourage vaccination when appropriate while acknowledging that uncertainty and unknowns remain. This message comes from a new commentary co-authored by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and other leading NIAID scientists in the journalAnnals of Internal Medicine.
Source: EurekAlert! - Infectious and Emerging Diseases - January 18, 2021 Category: Infectious Diseases Source Type: news
NIH experts discuss SARS-CoV-2 viral variants
(NIH/National Institute of Allergy and Infectious Diseases) The rise of significant variants of SARS-CoV-2 has attracted the attention of health and science experts worldwide. In an editorial published inJAMA, experts from the National Institute of Allergy and Infectious Diseases outline how these variants have arisen, concerns about whether vaccines currently authorized for use will continue to protect against new variants, and the need for a global approach to fighting SARS-CoV-2 as it spreads and acquires additional mutations.
Source: EurekAlert! - Infectious and Emerging Diseases - February 12, 2021 Category: Infectious Diseases Source Type: news
NIH-sponsored ACTIV-3 clinical trial closes enrollment into two sub-studies
(NIH/National Institute of Allergy and Infectious Diseases) The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198. The sub-studies were halted by the trial sponsor, the National Institute of Allergy and Infectious Diseases, on March 1, following an interim review and recommendation from the independent DSMB.
Source: EurekAlert! - Infectious and Emerging Diseases - March 5, 2021 Category: Infectious Diseases Source Type: news
NIH scientists use human cerebral organoid to test drug for deadly brain disease
(NIH/National Institute of Allergy and Infectious Diseases) Approximately two years after establishing a human cerebral organoid system to study Creutzfeldt-Jakob disease (CJD), National Institutes of Health researchers have further developed the model to screen drugs for potential CJD treatment. The scientists, from NIH's National Institute of Allergy and Infectious Diseases (NIAID), describe their work in Scientific Reports.
Source: EurekAlert! - Infectious and Emerging Diseases - March 9, 2021 Category: Infectious Diseases Source Type: news
NIH awards grants to support bacteriophage therapy research
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases has awarded $2.5 million in grants to 12 institutes to support research on bacteriophage therapy. These awards represent NIAID's first series of grants focused on research on this therapy, an emerging field that could yield new ways to fight antimicrobial-resistant bacteria. A 2019 report from CDC found that antibiotic-resistant pathogens cause more than 2.8 million infections in the U.S. each year and more than 35,000 people die.
Source: EurekAlert! - Infectious and Emerging Diseases - March 11, 2021 Category: Infectious Diseases Source Type: news
New insights on cause of anaphylaxis following COVID-19 vaccination
(Wiley) On the first day of the UK campaign for COVID-19 vaccination, there were reports of two cases of anaphylaxis a severe, potentially life-threatening allergic reaction within minutes of administration of the Pfizer/BioNTech mRNA vaccine. Subsequently further cases of suspected anaphylaxis to the Pfizer vaccine were reported. A new report published in Clinical& Experimental Allergy reveals that an allergy to the ingredient polyethylene glycol (PEG) is a cause of anaphylaxis to the vaccine. However, this is in the context of millions of doses safely administered.
Source: EurekAlert! - Infectious and Emerging Diseases - April 7, 2021 Category: Infectious Diseases Source Type: news
NIH experts discuss post-acute COVID-19
(NIH/National Institute of Allergy and Infectious Diseases) Many people who have COVID-19 make a full recovery and return to their baseline state of health; however, some people have symptoms or other sequelae weeks or months after initial SARS-CoV-2 infection. These symptoms were the subject of the " Workshop on Post-acute Sequelae of COVID-19 " hosted on Dec. 2 and 4, 2020, by the National Institute of Allergy and Infectious Diseases (NIAID), in collaboration with other institutes and centers of the NIH.
Source: EurekAlert! - Infectious and Emerging Diseases - April 13, 2021 Category: Infectious Diseases Source Type: news
